|
|
IRIS International In the News |
|
IRIS International to Acquire CLIA Certified Laboratory
|
CHATSWORTH, Calif., July 27, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that it has signed a definitive agreement to acquire AlliedPath, Inc., a private, early stage high complexity, CLIA-certified laboratory focused on oncology and molecular diagnostics for $4.7 million in cash, with an additional earn-out up to $1.3 million subject to the achievement of specific sales and earnings targets over the next three years. The acquisition, which is subject to customary closing conditions, is expected to close on or before July 30, 2010.
|
|
|
IRIS International Reports Record Second Quarter Revenue
|
CHATSWORTH, Calif., July 27, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), reflecting continued improved instruments sales and record sales of consumables and service, today announced revenue of $26.7 million for the second quarter ended June 30, 2010, a 19% increase from revenue of $22.3 million in the prior year second quarter and the highest revenue quarter in the Company's history. Net income for the second quarter 2010 was $624,000, or $0.03 per diluted share, compared with net income of $1.0 million, or $0.06 per diluted share, in the year ago period. Second quarter 2010 included unfavorable foreign currency fluctuation of approximately $800,000, primarily resulting from the precipitous drop in the Euro and British Pound currencies attributable to the European debt crisis, CFO severance and related costs of approximately $381,000 and acquisition related expenses of approximately $321,000. The total impact of these charges adversely impacted the second quarter earnings by approximately $0.06 per diluted share. We are presenting below a tabular presentation of what earnings and diluted EPS would have been had these charges not occurred. These non-GAAP financial measures are labeled as adjusted net income and adjusted diluted EPS. Diluted weighted average shares outstanding for the three months ended June 30, 2010 and 2009, were 18.1 million and 17.9 million, respectively.
|
|
|
IRIS to Webcast Financial Analyst and Investor Meeting at American Association for Clinical Chemistry (AACC) on Wednesday, July 28th
|
CHATSWORTH, Calif., July 22, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), will provide a live listen-only webcast of its financial analyst and investor breakfast meeting and presentation on Wednesday, July 28, 2010. The in-person breakfast meeting is scheduled to begin at 7:30 a.m. Pacific time, with the live webcast and presentation beginning thereafter at 8:00 a.m. PT. IRIS senior management, led by Chairman and CEO Cesar Garcia, will provide an overview and update of the Company's business. The analyst meeting is being held in conjunction with the American Association for Clinical Chemistry (AACC) 2010 Annual Meeting and Clinical Lab Expo in Anaheim, Calif.
|
|
|
IRIS to Release Second Quarter Financial Results and Host Conference Call and Webcast on Tuesday, July 27, 2010
|
CHATSWORTH, Calif., July 13, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), will release its second quarter 2010 financial results after the close of trading on Tuesday, July 27, 2010. IRIS management will also host a conference call and webcast that day at 4:30 P.M. Eastern Time, to discuss the second quarter results, as well as provide a general business update:
|
|
|
IRIS Renews Supply Agreement With Amerinet
|
CHATSWORTH, Calif., July 13, 2010 -- IRIS International, Inc. (Nasdaq:IRIS) a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, today announced a new supply agreement for its full product line of automated and semi-automated urinalysis systems, related products, consumables and services agreements, with Amerinet Inc., a leading national healthcare group purchasing organization (GPO) servicing more than 41,000 provider facilities, including 2,537 acute care hospitals. The new three-year sales and service supply agreement went into effect June 1, 2010.
|
|
|
IRIS Signs New Three-Year Supply Agreement with Premier, a Healthcare Alliance Representing 2,300 Hospitals
|
CHATSWORTH, Calif., July 12, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that its Iris Diagnostics Division has signed a new three-year supply agreement with Premier Purchasing Partners LP, the group purchasing unit of Premier, Inc., one of the nation's largest healthcare alliances, representing more than 2,300 U.S. hospitals and 67,000 other healthcare sites. The new contract, effective August 1, 2010 through July 31, 2013, is for Iris's full urinalysis product line including the iQ(R)200 Series Automated Urinalysis Systems, consumables and reagents, and Annual Service Agreements.
|
|
|
IRIS Honored by Premier Healthcare Alliance for Exceptional Supplier Performance
|
CHATSWORTH, Calif., July 6, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that it is the winner of the fifth annual Pinnacle Award presented by the Premier healthcare alliance.
|
|
|
IRIS International Submits 510(k) Application to FDA for iChem(R)VELOCITY(TM) Automated Urine Chemistry Analyzer and iRICELL(R) Urinalysis Workstation
|
CHATSWORTH, Calif., July 1, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Diagnostics Division submitted on June 30, 2010, a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for its iChem(r)Velocity(tm) Automated Urine Chemistry Analyzer and iRICELL(r) Urinalysis Workstation.
|
|
|
IRIS to Host Financial Analyst and Investor Meeting at American Association for Clinical Chemistry (AACC) 2010 Annual Meeting & Clinical Lab Expo in Anaheim on July 28th
|
CHATSWORTH, Calif., June 21, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that IRIS senior management, led by Cesar Garcia, Chairman and CEO, will host a financial analyst and investor breakfast meeting and presentation on Wednesday, July 28, 2010, in conjunction with the American Association for Clinical Chemistry (AACC) 2010 Annual Meeting and Clinical Lab Exposition in Anaheim, CA.
|
|
|
IRIS to Present at Jefferies 2010 Global Life Sciences Conference on June 10, 2010
|
CHATSWORTH, Calif., May 25, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that Chairman, President and Chief Executive Officer, Cesar M. Garcia, will present an overview of the Company at the Jefferies Global Life Sciences Conference, June 8-11, 2010 at the Grand Hyatt Hotel in New York City. Mr. Garcia is scheduled to present on Thursday, June 10 at 3:00 p.m. Eastern Time, and will be available for one-on-one meetings with institutional investors at the conference throughout the day.
|
|
|
IRIS to Participate at the 7th Annual Craig-Hallum Institutional Investor Conference June 2, 2010
|
CHATSWORTH, Calif., May 20, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that Thomas E. Warekois, Corporate Vice President and President of the Iris Diagnostics division, and Thomas H. Adams, Ph.D., Corporate Vice President and Chief Technology Officer, will be available for one-on-one meetings with institutional investors at the 7th Annual Craig-Hallum Institutional Investor Conference on Wednesday, June 2, 2010, at the Radisson Plaza Hotel in Minneapolis, Minnesota.
|
|
|
IRIS International Outlines Major Initiatives for 2010 and Beyond, With New Product Pipeline to Begin Generating Revenue and Earnings; Five New Product Releases Planned in 2010, and Development of Next Generation 3GEMS(TM) Program to Accelerate, Annual Meeting Told
|
CHATSWORTH, Calif., May 18, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, in outlining its major strategic initiatives for 2010 and beyond, told shareholders attending the Annual Meeting held here on Friday that the value created from its new product pipeline is now coming to fruition, as the Company is poised to begin generating its first revenues and earnings from five product releases in 2010, a pipeline that expands the Company's addressable market opportunity to nearly $4 billion from $450 million previously.
|
|
|
IRIS International Corporate Vice President and CFO Peter L. Donato Resigns
|
CHATSWORTH, Calif., May 12, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that Corporate Vice President and Chief Financial Officer Peter L. Donato has resigned. Mr. Donato has served as Chief Financial Officer of IRIS since August 2007. Martin S. McDermut, a highly seasoned financial executive who previously served as CFO of IRIS from 1995 to 1999, has joined the Company as Acting Chief Financial Officer while the Company initiates a search for a permanent replacement, for which it has engaged a nationally recognized executive recruiting firm.
|
|
|
IRIS International Reports Record First Quarter Revenue Spurred by Strong IVD Instrument Sales and Record Consumables and Service Revenue
|
CHATSWORTH, Calif., May 3, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), reflecting continued improved instruments sales and record sales of consumables and service, today announced revenue of $26.0 million for the first quarter ended March 31, 2010, a 20% increase from revenue of $21.6 million in the prior year first quarter. Net income in the 2010 first quarter of $1.04 million, or $0.06 per diluted share, compares with net income of $1.4 million, or $0.08 per diluted share, in the year ago period, reflecting a 20% increase in operating expenses, including a 31% increase in R&D expense. Diluted weighted average shares outstanding for the three months ended March 31, 2010 and 2009, were 18.2 million and 17.8 million, respectively.
|
|
|
IRIS International Submits 510(k) Application to FDA for NADiA(R) ProsVue(TM) for Identifying Post-Prostatectomy Patients With Low Risk of Prostate Cancer Recurrence
|
CHATSWORTH, Calif., April 29, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Molecular Diagnostics (IMD) subsidiary has submitted a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for NADiA(r)ProsVue(tm), a prostate cancer prognostic test. The test is designed to help physicians identify patients at low risk of cancer recurrence post radical prostatectomy.
|
|
|
IRIS International Renews Supply Agreement With MedAssets
|
CHATSWORTH, Calif., April 26, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that it has renewed a supply agreement for its full product line of automated and semi-automated urinalysis systems, related products, consumables and services agreements, with MedAssets Supply Chain Systems, one of the largest Group Purchasing Organizations (GPOs) serving healthcare providers nationwide. The new three-year contract is effective April 1, 2010.
|
|
|
IRIS International Releases Annual Letter to Shareholders
|
CHATSWORTH, Calif., April 20, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that it has released its Annual Letter to Shareholders in its 2009 Annual Report, which was mailed to Shareholders in advance of its Annual Meeting of Stockholders to be held at the Company's corporate headquarters at 9158 Eton Avenue, Chatsworth, Calif., on Friday, May 14, 2010, at 10:00 a.m. Pacific time. The letter, from Chairman, President and Chief Executive Officer, Cesar Garcia, highlights the achievements and activities of 2009 and early 2010, and planned initiatives and outlook for the balance of the year. The text of the Shareholder Letter follows:
|
|
|
IRIS to Release First Quarter Financial Results and Host Conference Call and Webcast on Monday, May 3, 2010
|
CHATSWORTH, Calif., April 15, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), will release its first quarter 2010 financial results after the close of trading on Monday, May 3, 2010. IRIS management will also host a conference call and webcast that day at 4:30 P.M. Eastern Time, to discuss the first quarter results, as well as provide a general business update:
|
|
|
IRIS to Release First Quarter Financial Results and Host Conference Call and Webcast on Monday, May 3, 2010
|
CHATSWORTH, Calif., April 15, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), will release its first quarter 2010 financial results after the close of trading on Monday, May 3, 2010. IRIS management will also host a conference call and webcast that day at 4:30 P.M. Eastern Time, to discuss the first quarter results, as well as provide a general business update:
|
|
|
IRIS International Receives Third Consecutive Omega NorthFace Award for Excellence in Customer Service
|
CHATSWORTH, Calif., March 25, 2010 -- Iris Diagnostics, a division of IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that it was awarded the 2009 Omega NorthFace ScoreBoard AwardSM, the third year in a row it has received the honor. The award program, now in its tenth (10th) year, is presented annually by the Omega Management Group Corp. to companies who achieved excellence in customer satisfaction during the prior calendar year. Omega Management Group specializes in driving companies' revenues and profits by implementing Customer Experience Management (CEM) strategies that increase customer and employee satisfaction.
|
|
|
IRIS International Launches Redesigned Website
|
CHATSWORTH, Calif., March 17, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, announced today the launch of its new and improved corporate website at www.proiris.com, featuring a newly designed homepage and enhanced navigation tools with access to the latest company information.
|
|
|
IRIS International's Sample Processing Division Expands Position in Thin Layer Sample Preparation
|
CHATSWORTH, Calif., March 16, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer and marketer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that its Sample Processing Division has initiated shipments of its new 12 place cytocentrifuge, the Statspin(r) CytoFuge(r) 12.
|
|
|
IRIS International to Present at Sidoti & Company's 14th Annual Emerging Growth Institutional Investor Forum
|
CHATSWORTH, Calif., March 11, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that it will be presenting at Sidoti & Company's 14th Annual Emerging Growth Institutional Investor Forum at 1:30 p.m. Eastern time on Wednesday, March 24, 2010 at The Grand Hyatt Hotel in New York City. Cesar Garcia, IRIS Chairman, President and Chief Executive Officer, will present an overview of the Company followed by Q&A. A copy of the presentation will be available on the Company's web site at www.proiris.com.
|
|
|
IRIS International Reports Fourth Quarter Results Reflecting Improved Instrument Sales and Record Consumables and Service Revenue
|
CHATSWORTH, Calif., March 1, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), reflecting improved instruments sales and record sales of consumables and service, today announced revenue of $26.5 million for the fourth quarter ended December 31, 2009, relatively flat from revenue of $26.7 in the prior year fourth quarter. Net income in the 2009 fourth quarter of $1.9 million, or $0.11 per diluted share, which included a one-time accrual of $0.5 million, or $0.02 per diluted share, for payroll taxes attributable to the exercise of stock options, compares with net income of $3.4 million, or $0.18 per diluted share, in the year ago period, which included a one-time gain of $1.2 million, or $0.04 per diluted share, related to the manufacturing transition and licensing agreement signed with IDEXX Laboratories in December 2008. Diluted weighted average shares outstanding for the three months ended December 31, 2009 and 2008, were 18.0 million and 18.5 million, respectively.
|
|
|
IRIS International Signs Three-Year Agreement With HealthTrust Purchasing Group
|
CHATSWORTH, Calif., Feb. 25, 2010 -- IRIS International Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that it has entered into a first-time three-year sales and service supply agreement with HealthTrust Purchasing Group, LP (HealthTrust), a leading national group purchasing organization (GPO).
|
|
|
IRIS to Release Fourth Quarter Financial Results and Host Conference Call and Webcast on March 1, 2010
|
CHATSWORTH, Calif., Feb. 3, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), will release its fourth quarter and year-end 2009 financial results after the close of trading on Monday, March 1, 2010. IRIS management will also host a conference call and webcast that day at 4:30 P.M. Eastern Time, to discuss the fourth quarter results, as well as provide a general business update, including a progress report on its NADiA(r) ProsVue(tm) ultra sensitive prostate-specific antigen diagnostic assay and its iChem(r)VELOCITY(tm) urine chemistry analyzer new product initiatives.
|
|
|
IRIS International Board Adopts Majority Vote Standard for Election of Directors
|
CHATSWORTH, Calif., Jan. 20, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its Board of Directors has approved an amendment to the Company's by-laws to adopt a majority vote standard for election of directors, beginning with the next election of directors at the Company's Annual Meeting of Stockholders in May.
|
|
|
IRIS International and Digital Images Diagnostic (China) Establish Strategic Partnership to Market IRIS's Complete Urinalysis Product Line in China
|
CHATSWORTH, Calif., Jan. 19, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, has entered into a strategic partnership with Digital Images Diagnostic (China), Ltd.
|
|
|
IRIS International Completes Purchase of Its German and UK Business From Distributor for Book Value
|
CHATSWORTH, Calif., Jan. 12, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that it had completed the purchase at book value of certain assets relating to the current distribution of Iris' products in the UK and Germany by the company's European distributor, IL UK and IL Germany of the Werfen Group. The assets purchased from IL UK and IL Germany consist primarily of customer leases related to the installed base of approximately 50 iQ(R)200 IRIS instruments and service contracts in those countries, which were valued at $840,000 as December 31, 2009.
|
|
|
IRIS International Elects Rick Timmins to Board of Directors
|
CHATSWORTH, Calif., Jan. 5, 2010 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that it has elected Rick Timmins, a highly seasoned executive with more than 30 years of senior finance experience, to its Board of Directors and as a member of the Audit Committee, increasing the number of independent directors to seven.
|
|
|
IRIS International Names David W. Gates, Ph.D. as Vice President, Quality and Regulatory Affairs
|
CHATSWORTH, Calif., Dec. 17, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that it has appointed David W. Gates, Ph.D., to the newly-created position of Vice President, Quality and Regulatory Affairs. Dr. Gates' primary focus will be the formulation and implementation of regulatory strategies for all company units, including Iris Diagnostics, Iris Molecular Diagnostics (IMD) and Iris Sample Processing (ISP) business units, as well as overseeing all U.S. and international regulatory filings, in support of the advancement of the Company's existing and emerging product pipeline.
|
|
|
IRIS International to Host One-on-One Meetings in San Francisco With Financial Analysts and Fund Managers on January 13, 2010
|
CHATSWORTH, Calif., Dec. 14, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that management will host a series of one-on-one meetings with analysts and fund managers on Wednesday, January 13, 2010, to be held at the Hilton San Francisco, 333 O'Farrell Street, San Francisco, Ca. The full day of meetings is being organized alongside the 28th Annual J.P. Morgan Healthcare Conference in San Francisco.
|
|
|
IRIS International to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009
|
CHATSWORTH, Calif., Nov. 19, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that Chairman, President and Chief Executive Officer Cesar Garcia will present an overview of the Company at the 21st Annual Piper Jaffray Health Care Conference on Tuesday, December 1, 2009 at 2:30 p.m. Eastern time at the New York Palace Hotel in New York City.
|
|
|
IRIS International's Sample Processing Division Enters Veterinary Ova and Parasite Detection Market With New Novel Sample Processing Kit
|
CHATSWORTH, Calif., Nov. 17, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer and marketer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that its Sample Processing Division has initiated shipments of its new StatSpin(R) OvaTube(TM) System for use in veterinary hospitals, clinics and reference laboratories to process fecal samples for the detection of ova and parasites.
|
|
|
IRIS International Names Lawrence J. Blecka, Ph.D., as Vice President, Research and Development of Iris Diagnostics Business Unit
|
CHATSWORTH, Calif., Nov. 11, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that it has appointed Lawrence J. Blecka, Ph.D., a senior executive with 30 years experience in medical device, diagnostics and biotechnology companies ranging from Fortune 500 to start-ups, as Vice President, Research and Development. Dr. Blecka will be responsible for overseeing all research and development of the Iris Diagnostics division, in support of the advancement of the Company's existing and emerging product pipeline.
|
|
|
IRIS International Reports Third Quarter Operating Income Up 7% and Net Earnings Up 18%, Bolstered by Record Consumables and Service and Improved Cost Efficiencies
|
CHATSWORTH, Calif., Oct. 27, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), bolstered by record contributions from sales of consumables and service and improved cost efficiencies, today announced third quarter operating income increased 7% to $2.3 million and net profits increased 18% to $1.9 million, or $0.11 per diluted share, the highest in any third quarter period, despite a 5% decline in overall revenue to $22.2 million as a result of lower U.S. instrument sales, for the third quarter ended September 30, 2009. This compares with operating income of $2.2 million and net earnings of $1.6 million, or $0.09 per diluted share, on revenue of $23.4 million in the prior year third quarter. Diluted weighted average shares outstanding for the three months ended September 30, 2009 and 2008, were 17.9 million and 18.8 million, respectively.
|
|
|
IRIS International Reports Initiation of Pivotal Retrospective Clinical Study Using NADiA(TM) ProsVue(TM) for Identifying Post-Prostatectomy Patients With Low Risk of Prostate Cancer Recurrence
|
CHATSWORTH, Calif., Oct. 26, 2009 -- IRIS International, Inc. (Nasdaq:IRIS) announced today that it has received Institutional Review Board (IRB) approvals from Duke University Medical Center, Memorial Sloan Kettering Cancer Institute, Eastern Virginia Medical School and the University of Washington Medical Center to immediately begin a multi-center 300 patient retrospective randomized clinical study utilizing its NADiA(TM) ProsVue(TM) ultra sensitive prostate-specific antigen diagnostic assay.
|
|
|
IRIS to Present at Oppenheimer 20th Annual Healthcare Conference in New York, November 3, 2009
|
CHATSWORTH, Calif., Oct. 22, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that Chief Financial Officer, Peter L. Donato, will present an overview of the Company at The Oppenheimer 20th Annual Healthcare Conference on Tuesday, November 3, 2009, at 1:00 p.m. Eastern time at the Waldorf Astoria Hotel in New York City.
|
|
|
IRIS International to Buy Its German and UK Business From Distributor for Book Value, as Prelude to Initiating Program for Expanding Direct International Sales; Management in Place
|
CHATSWORTH, Calif., Sept. 22, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that it has signed a letter of intent to acquire from its European distributor, The Werfen Group, assets relating to its current distribution of IRIS' products in the UK and Germany. The assets to be purchased consist primarily of customer leases for installed IRIS instruments and service contracts, valued at inventory book value. The parties presently are negotiating a definitive acquisition agreement, and IRIS expects to consummate the acquisition at the end of December 2009.
|
|
|
IRIS to Present At UBS Annual Global Life Sciences Conference
|
CHATSWORTH, Calif., Sept. 10, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that Chairman, President and Chief Executive Officer Cesar Garcia will present an overview of the Company at the UBS annual Global Life Sciences Conference at 1:00 p.m. Eastern time on Tuesday, Sept. 22, 2009 at the Grand Hyatt Hotel in New York City.
|
|
|
IRIS International and Fujirebio Sign Exclusive Distribution Agreement
|
CHATSWORTH, Calif., Aug. 20, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, has entered into a distribution agreement with Fujirebio Inc., one of the largest in vitro diagnostics (IVD) companies in Japan. The two companies made the announcement today.
|
|
|
IRIS to Present At the Canaccord Adams 29th Annual Global Growth Conference August 13, 2009
|
CHATSWORTH, Calif., Aug. 3, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that Chairman, President and Chief Executive Officer Cesar Garcia will present an overview of the Company at the Canaccord Adams 29th Annual Global Growth Conference at 11:00 a.m. Eastern time on Thursday, August 13, 2009 at the Intercontinental Hotel in Boston, Mass.
|
|
|
IRIS International Reports Second Quarter 2009 Financial Results
|
CHATSWORTH, Calif., July 30, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced revenue of $22.3 million for the second quarter ended June 30, 2009, a decrease of 6% from revenue of $23.8 million in the year ago second quarter. Net income for the 2009 second quarter was $1.0 million, or $0.06 per share, compared with $2.2 million, or $0.12 per share in the year ago period.
|
|
|
IRIS International Announces Preliminary Second Quarter 2009 Operating Results
|
CHATSWORTH, Calif., July 21, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that, ahead of its planned analysts breakfast briefing tomorrow, Wednesday, July 22 at the AACC 2009 Annual Meeting and Clinical Lab Expo in Chicago, it is pre-releasing selected preliminary results and providing an update on operations for the second quarter ended June 30, 2009.
|
|
|
IRIS to Host Financial Analyst Briefing At American Association for Clinical Chemistry (AACC) 2009 Annual Meeting and Clinical Lab Expo in Chicago On July 22nd
|
CHATSWORTH, Calif., June 29, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that IRIS senior management, led by Cesar Garcia, Chairman and CEO, will host a financial analyst breakfast briefing and presentation on Wednesday, July 22, 2009, in conjunction with the American Association for Clinical Chemistry (AACC) 2009 Annual Meeting and Clinical Lab Exposition in Chicago, IL.
|
|
|
IRIS Honored by Premier Healthcare With Prestigious Supplier Pinnacle Award for Performance Excellence
|
CHATSWORTH, Calif., June 18, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that it is the winner of the fourth annual Supplier Pinnacle Award presented by Premier Purchasing Partners, LP, the group purchasing unit of the Premier healthcare alliance.
|
|
|
IRIS to Present At the 6th Annual Craig-Hallum Institutional Investor Conference June 11, 2009
|
CHATSWORTH, Calif., June 2, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that Chairman, President and Chief Executive Officer Cesar M. Garcia will present an overview of the Company at the 6th Annual Craig-Hallum Institutional Investor Conference at 2:00 p.m. Central time on Thursday, June 11, 2009 at the Radisson Plaza Hotel in Minneapolis, Minnesota.
|
|
|
IRIS International Elects Noted Cancer Expert, Dr. Beth Y. Karlan, to Board of Directors
|
CHATSWORTH, Calif., May 27, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, has elected Dr. Beth Y. Karlan to its Board of Directors, it was announced today by Cesar M. Garcia, Chairman, President and Chief Executive Officer. "The addition to our Board of such a distinguished cancer scientist and physician as Dr. Karlan underscores our commitment not only to our core business but to our belief in the importance of our NADiA(r) (nucleic acid detection immunoassay) technology platform with applications in early detection of relapse in prostate cancer, AIDS and other diseases," said Mr. Garcia. "Dr. Karlan's expertise in early detection of cancer, genetics and biomarkers which form a molecular signature that predicts response to therapy and survival, makes her an ideal corporate Director for Iris as we advance in our research, development and commercialization of our molecular diagnostics and advanced hematology platforms. She brings unique skills and an impressive record of clinical and educational contributions to the advancement of cancer treatment and detection."
|
|
|
UPDATING and REPLACING -- IRIS International Remains On Track for Meeting 2009 Guidance After Resuming Full-Scale Shipments of iChem(r)Velocity(tm) Automated Chemistry Analyzer to International Market, Annual Meeting Told
|
CHATSWORTH, Calif., May 26, 2009 -- In a release issued earlier today by IRIS International, Inc. (Nasdaq:IRIS) under the same headline, please note the addition of Stephen E. Wasserman as a board of director. The updated release follows.
|
|
|
IRIS International Remains On Track for Meeting 2009 Guidance After Resuming Full-Scale Shipments of iChem(r)Velocity(tm) Automated Chemistry Analyzer to International Market, Annual Meeting Told
|
CHATSWORTH, Calif., May 26, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, "following resumption of full-scale shipments of its new iChem(r)Velocity(tm) Automated Urine Chemistry Analyzers to the international market, remains on track for achieving its previously announced guidance for the current second quarter ending June 30, and for the full year ending December 31, 2009," Cesar Garcia, Chairman and Chief Executive Officer, told shareholders attending its Annual Meeting held here on Friday.
|
|
|
IRIS Resumes Full-Scale Shipments of iChem(r)VELOCITY(tm) Automated Urine Chemistry Analyzer to International Market
|
CHATSWORTH, Calif., May 21, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that following the validation of previously announced design improvements, it has resumed full-scale shipments of its new iChem(r)Velocity(tm) Automated Chemistry Analyzers to the International Market.
|
|
|
IRIS Honored by MedAssets Supply Chain Systems With Group Buy Excellence and Gold Vendor Awards
|
CHATSWORTH, Calif., May 4, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that its IRIS Diagnostics Business Unit has been honored with a Group Buy Excellence Award and Gold Vendor Award by MedAssets Supply Chain Systems, one of the largest U.S. group purchasing and supply chain organizations.
|
|
|
IRIS International Reports First Quarter 2009 Financial Results
|
CHATSWORTH, Calif., April 29, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced revenue of $21.6 million for the first quarter ended March 31, 2009, which is the same as the year ago first quarter revenue. Net income for the 2009 quarter was $1.4 million, or $0.08 per share, compared with $1.8 million, or $0.10 per share in the year ago period.
|
|
|
IRIS International Celebrates 30 Years of Excellence as Leading In-Vitro Diagnostics Company
|
CHATSWORTH, Calif., April 3, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), this week proudly celebrates 30 years of excellence as a leading in vitro diagnostics company, having evolved from its founding in 1979 as a fledgling research and development stage company with no revenue, to a company today approaching $100 million in sales and more than 300 employees serving the needs of urinalysis across the globe, delivering iQ brand recognized system automation and improving efficiency and quality at laboratories in more than 60 countries, Cesar Garcia, Chairman, President and Chief Executive Officer, announced today.
|
|
|
IRIS International Board Appoints Edward F. Voboril as New Independent Lead Director
|
CHATSWORTH, Calif., March 17, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that current IRIS director Edward F. Voboril has been appointed new independent lead director, replacing Richard H. Williams who will leave the IRIS Board of Directors as of the Company's next annual meeting, as previously announced.
|
|
|
IRIS International to Present At Sidoti & Company's 13th Annual Emerging Growth Institutional Investor Forum
|
CHATSWORTH, Calif., March 11, 2009 -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that it will be presenting at Sidoti & Company's 13th Annual Emerging Growth Institutional Investor Forum at 11:00 a.m. Eastern time on Wednesday, March 25, 2009 at The Grand Hyatt Hotel in New York City. Peter Donato, IRIS Corporate Vice President and Chief Financial Officer, will present an overview of the Company followed by Q&A. A copy of the presentation will be available on the Company's web site at www.proiris.com.
|
|
|
|
|
